How do you approach chronic active AMR concurrent with changes of CNI toxicity?

This can be a tricky situation. With AMR, my approach is to optimize the antiproliferative agents (mycophenolate) and maintain therapeutic levels of the CNI. Adjusting the CNI target level will be dependent on the degree of CNI toxicity, if present. Maybe for mild changes, run the tact levels in the...